Drospirenone increases central and peripheral β-endorphin in ovariectomized female rats

Menopause

Volumn 14, Issue 1, 2007, Pages 63-73

  Genazzani, Andrea Riccardo ^a   Pluchino, Nicola ^a   Begliuomini, Silvia ^a   Pieri, Matteo ^a   Centofanti, Manolo ^a   Freschi, Letizia ^a   Casarosa, Elena ^a   Luisi, Michele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Endorphin; Allopregnanolone; Central nervous system; Drospirenone; Rats

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; BETA ENDORPHIN; DROSPIRENONE; ESTRADIOL VALERATE;

ADENOHYPOPHYSIS; ADRENAL GLAND; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HYPOPHYSIS INTERMEDIATE LOBE; HYPOTHALAMUS; NONHUMAN; OVARIECTOMY; PARIETAL LOBE; PERIPHERAL NERVOUS SYSTEM; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ALDOSTERONE ANTAGONISTS; ANDROSTENES; ANIMALS; BETA-ENDORPHIN; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ESTRADIOL; FEMALE; OVARIECTOMY; PREGNANOLONE; RATS; RATS, WISTAR;

EID: 33846035802     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000230348.05745.7d     Document Type: Article

References (42)

1. Petraglia F, Penalva A, Locatelli V, et al. Effect of gonadectomy and gonadal steroid replacement on pituitary and plasma β-endorphin levels in the rat. Endocrinology 1982;111:1224-1229.
2. Genazzani AR, Petraglia F, Facchinetti F, Grasso A, Alessandrini G, Volpe A. Steroid replacement treatment increases β-endorphin and β-lipotropin plasma levels in postmenopausal women. Gynecol Obstet Invest 1988;26:153-159.
3. Genazzani AR, Petraglia F, Bergamaschi M, Genazzani AD, Facchinetti F, Volpe A. Progesterone and progestins modulate β-endorphin concentrations in the hypothalamus and in the pituitary of castrated female rats. Gynecol Endocrinol 1987;1:61-69.
4. Genazzani AR, Bernardi F, Pluchino N, et al. Effect of tibolone administration on central and peripheral levels of allopregnanolone and β-endorphin in female rats. Menopause 2006;13:57-64.
5. Corpechot C, Young J, Calvel M, et al. Neurosteroids: 3 α-hydroxy-5 α-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology 1993;133:1003-1009.
6. Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAA receptor: mechanism of action and physiological significance. Prog Neurobiol 1992;38:379-395.
7. Lambert JJ, Belelli D, Peters CA. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 1995;16:295-303.
8. Rupprecht R, Holsboer F. Neuropsychopharmacological properties of neuroactive steroids. Steroids 1999;64:83-91.
9. Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004;123:349-359.
10. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 2005;22:106-118.
11. Ghoumari AM, Ibanez C, El-Etr M, et al. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 2003;86:848-859.
12. Genazzani AR, Stomati M, Bernardi F, et al. Conjugated equine estrogens reverse the effects of aging on central and peripheral allopregnanolone and β-endorphin levels in female rats. Fertil Steril 2004;81:757-766.
13. Stomati M, Bernardi F, Luisi S, et al. Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and β-endorphin. Maturitas 2002;43:195-206.
14. de Wit H, Scmitt L, Purdy R, Hauger R. Effects of acute progesterone administration in healthy menopausal women and normally-cycling women. Psychoneuroendocrinology 2001;26:697-710.
15. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995;7:171-177.
16. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8:3-63.
17. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 2003;100:10506-10511.
18. Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745-5756.
19. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
20. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-251.
21. Bernardi F, Salvestroni C, Casarosa E, et al. Aging is associated with changes in allopregnanolone concentrations in brain, endocrine glands and serum in male rats. Eur J Endocrinol 1998;138:316-321.
22. Bernardi F, Stomati M, Luisi S, Pieri M, Latrie F, Genazzani AR. Effects of the new generation selective estrogen modulator EM-652 and oral administration of estradiol valerate on circulating, brain and adrenal β-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertil Steril 2002;77:1018-1027.
23. Paoletti AM, Lello S, Fratta S, et al. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol. Fertil Steril 2004;81:645-651.
24. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
25. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 μg on premenstrual symptoms. Contraception 2005;71:1-7.
26. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189-196.
27. Genazzani AR, Bernardi F, Pluchino N, et al. Endocrinology of menopausal transition and its brain implications. CNS Spectr 2005;10:449-457.
28. Mains RE, Eipper BA. Synthesis and secretion of corticotropins, melanotropins, and endorphins by rat intermediate pituitary cells. J Biol Chem 1979;25:7885-7894.
29. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988;11:308-314.
30. Pollow K, Juchem M, Elger W, Jacobi N, Hoffman G, Mobus V. Dihydrospirorenone (ZK30595): a novel synthetic progestogen - characterization of binding to different receptor proteins. Contraception 1992;46:561-574.
31. Muhn P, Fuhrmann U, Fritzmeier H, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-335.
32. Watzka M, Bidlingmaier F, Beyenburg S, et al. Corticosteroid receptor mRNA expression in the brains of patients with epilepsy. Steroids 2000;65:895-901.
33. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and in disease. Endocr Rev 1998;19:269-301.
34. McEwen BS, Cameron H, Chao HM, et al. Resolving a mystery: progress in understanding the function of adrenal steroid receptors in hippocampus. Prog Brain Res 1994;100:149-155.
35. Castren M, Patchev VK, Almeida OF, Holsboer F, Trapp T, Castren E. Regulation of rat mineralcorticoid receptor expression in neurons by progesterone. Endocrinology 1995;136:3800-3806.
36. Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 2000;25:513-518.
37. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 1998;83:3339-3345.
38. Genazzani AR, Petraglia F, Mercuri N, et al. Effect of steroid hormones and antihormones on hypothalamic β-endorphin concentrations in intact and castrated female rats. J Endocrinol Invest 1990;13:91-96.
39. Chowen JA, Argente J, Vican L, Clifton DK, Steiner RA. Proopiomelanocortin messenger RNA in hypothalamic neurons is increased by testosterone through aromatization to estradiol. Neuroendocrinology 1990;52:581-588.
40. Blum M, Roberts JL, Wardlaw SL. Androgen regulation of proopiomelanocortin gene expression and peptide content in the basal hypothalamus. Endocrinology 1989;124:2283-2288.
41. Selmanoff M, Shu C, Hartman RD, Barraclough CA, Petersen SL. Tyrosine hydroxylase and POMC mRNA in the arcuate region are increased by castration and hyperprolactinemia. Mol Brain Res 1991;10:277-281.
42. Bernardi F, Pieri M, Stomati M, et al. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women. Gynecol Endocrinol 2003;17:65-77.